key: cord-0265807-coog2lfi
authors: Junker, D.; Becker, M.; Wagner, T.; Kaiser, P. D.; Maier, S.; Grimm, T. M.; Griesbaum, J.; Marsall, P.; Gruber, J.; Traenkle, B.; Heinzel, C.; Pinilla, Y. T.; Held, J.; Fendel, R.; Kreidenweiss, A.; Nelde, A.; Maringer, Y.; Schroeder, S.; Walz, J. S.; Althaus, K.; Uzun, G.; Mikus, M.; Bakchoul, T.; Schenke-Layland, K.; Bunk, S.; Haeberle, H.; Bitzer, M.; Goepel, S.; Renk, H.; Remppis, J.; Engel, C.; Franz, A. R.; Harries, M.; Kessel, B.; Strengert, M.; Krause, G.; Zeck, A.; Rothbauer, U.; Dulovic, A.; Schneiderhan-Marra, N.
title: Antibody binding and ACE2 binding inhibition is significantly reduced for the Omicron variant compared to all other variants of concern
date: 2022-01-01
journal: nan
DOI: 10.1101/2021.12.30.21267519
sha: 23ef8e1fe6dd7fb1eeda6ed1c07f3fb5296d35d4
doc_id: 265807
cord_uid: coog2lfi

The rapid emergence of the Omicron variant and its large number of mutations has led to its classification as a variant of concern (VOC) by the WHO. Initial studies on the neutralizing response towards this variant within convalescent and vaccinated individuals have identified substantial reductions. However many of these sample sets used in these studies were either small, uniform in nature, or were compared only to wild-type (WT) or, at most, a few other VOC. Here, we assessed IgG binding, (Angiotensin-Converting Enzyme 2) ACE2 binding inhibition, and antibody binding dynamics for the omicron variant compared to all other VOC and variants of interest (VOI), in a large cohort of infected, vaccinated, and infected and then vaccinated individuals. While omicron was capable of binding to ACE2 efficiently, antibodies elicited by infection or immunization showed reduced IgG binding and ACE2 binding inhibition compared to WT and all VOC. Among vaccinated samples, antibody binding responses towards omicron were only improved following administration of a third dose. Overall, our results identify that omicron can still bind ACE2 while pre-existing antibodies can bind omicron. The extent of the mutations appear to inhibit the development of a neutralizing response, and as a result, omicron remains capable of evading immune control.

Since its initial outbreak in late 2019, SARS-CoV-2 has morphed into a global pandemic, characterised by waves of infection within countries and regions.

Following the initial global wave, subsequent waves have often been triggered by the emergence of variants of concern that outcompeted earlier variants, which have increased transmission or show the ability to escape vaccine and infection-derived immunity (10) (11) (12) (13) (14) (15) . Several of these variants have been classified as variants of concern (VOC) by the WHO (9), with the delta variant currently being responsible for the majority of active infections globally (16). Due to concerns that its numerous spike protein mutations would render it able to escape immune control and its rapid spread in South Africa, the WHO classified omicron as a VOC on the 26 th of November 2021

(1). Within days of this classification, omicron had already been reported in multiple other countries and has now been shown to be responsible for increasing case numbers in South Africa(17), while also appearing to have a higher risk of reinfection (18) . Early studies into neutralization against omicron have identified significant reductions in neutralizing activity, especially for those who have not received three vaccine doses (2) (3) (4) 19) . However these studies have also often featured a low sample number, a limited diversity of sample types (e.g. only those vaccinated with Pfizer BNT162b2), or directly compared omicron to WT or a single other variant of concern. We provide here a comprehensive analysis of the binding capacity, binding dynamics and ACE2 binding inhibition of omicron towards antibodies generated through either vaccination or natural infection compared to WT and all other VOCs as well as the lambda and mu variants of interest (VOI). In contrast to these studies, we have included samples from a range of vaccines and dosing schemes currently available within the EU including boosters, and from . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint infected samples from both adults and children from the first, second and third waves in Germany.

We analyzed antibody binding responses towards omicron, all other variants of concern/interest and wild-type in sera from individuals with either vaccine-induced (vaccinated), naturally-induced (convalescent) or naturally-induced and vaccineboosted immunity (infected and vaccinated). We included samples from convalescent individuals from all three waves in Germany so far (first wave, WT n=50, second wave, alpha n=30, third wave, delta n=6), individuals vaccinated twice with two homologous doses of either mRNA-1273 (n=46), AZD1222 (n=60) or BNT162b2 (n=60), individuals vaccinated twice with two heterologous doses of either AZD1222 and mRNA-1273 (n=20) or BNT162b2 (n=20), individuals vaccinated three times with BNT162b2 (n=20) or individuals with a previous SARS-CoV-2 infection who were later vaccinated with a single dose of BNT162b2 (n=25). As controls for unvaccinated individuals, commercially available pre-pandemic sera were used (n=15). Please consult Table 1 for a full description of the characteristics of the samples used in this study.

Initially, we examined IgG binding using MULTICOV-AB (20) , a previously published SARS-CoV-2 multiplex immunoassay that was adapted to analyze binding towards RBDs from all VOC/VOI (a full list of antigens analyzed and their mutations contained within can be found as Table 2 ). For both vaccinated and convalescent samples, IgG binding towards omicron from pre-existing antibodies was significantly reduced compared to WT (vaccinated 4.5x fold decrease, infected 8.6 fold, Supplementary is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint Delta which currently still comprises the majority of global infections was reduced 1.2-1.3 fold compared to WT, and thus was still 3.5-6.3 fold greater than omicron (Supplementary Table 1 and 2). Next, we analyzed ACE2 binding inhibition as proxy for neutralization using RBDCoV-ACE2(21), a multiplex ACE2-RBD inhibition assay.

This assay mimics the interaction between ACE2 and the RBD, analyzing the presence of antibodies which block said interaction, while the multiplex format allows for the simultaneous measurement of all VOCs/VUIs in a single well. To evaluate binding against other antigens of SARS-CoV-2, we also include the Spike and S1

domain of WT and the Spike of omicron. In contrast to IgG binding, ACE2 binding inhibition against the omicron RBD was substantially reduced compared to WT is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint As all other publications on neutralization against omicron had involved either pseudoviruses expressing the full-length spike (2, (5) (6) (7) , or the native virus itself (3, 8, 19) , we analyzed omicron ACE2 binding inhibition against the Spike protein. Omicron ACE2 binding inhibition towards the Spike protein, while still significantly reduced compared to WT (p<0.001), was still present in 6.8% of samples (4.5% for RBD) ( Figure 2a ). In contrast, IgG binding capacity towards the Spike was more conserved than the RBD (Figure 2 

Next, we analyzed whether vaccine type (AZD1222, mRNA-1273 or BNT162b2) and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. In this study, we provide an in-depth characterization of antibody binding to omicron as compared to WT and all other VOCs and VUIs in a large diverse sample cohort.

The use of an ACE2 inhibition assay enabled the comparison of multiple variants of interest simultaneously and was neutralizing antibody specific, while also producing comparable results to classical virus neutralization assays (21) . Antibody binding towards the omicron variant elicited by either immunization or previous infection, is substantially reduced when compared with other variants. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint Our data are in line with several other initial reports (2) (3) (4) (5) (6) (7) (8) 22) and provide additional information on IgG binding capacity and ACE2 binding inhibition by the inclusion of a large variety of sub-cohorts representing the present diversity of immunity against SARS-CoV-2, and by the comparison of the omicron variant to all other VOC/VOI. We found that both IgG binding capacity and ACE2 binding inhibition was more severely reduced for all samples against the omicron variant, than against any other VOC/VOI, with most samples being classified as non-responsive towards omicron for Our results are in agreement that either vaccine protection from two doses or natural immunity generated by a previous infection, appears broadly ineffective against omicron (18) . Among those who had received two doses, binding responses were is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint consistent with other reports (2) in identifying a significant decrease for those who received homologous two-dose vector vaccination as opposed to homologous mRNA vaccination or heterologous vaccination.

We identified no difference in binding response for children compared to adults.

While previous research has identified that children's antibody titres are higher than adults following infection (24), this did not result in an increase in binding capacity or ACE2 binding inhibition toward omicron. However, a limitation of our study is that the Similarly to (22) , we identified the same pattern of a much less pronounced reduction in RBD IgG binding response compared to RBD-directed neutralizing activity. Our analysis of both the Spike and RBD derived ACE2 binding inhibition suggests that this is consistent for both. Given that the Spike-derived antibodies had the same pattern of decreased neutralizing activity compared to IgG binding response, this suggests that while both epitopes are sufficiently conserved to enable binding, their divergent mutated sequences affect their neutralizing response. Further investigation into this pattern and particularly the role of S1-derived antibodies in neutralization is required to understand the neutralizing protection offered against omicron.

Overall, our results identify that while omicron can still can bind ACE2 and preexisting antibodies can bind omicron, the extent of the mutations within the RBD appear to be too divergent to enable RBD-directed antibodies to mount a neutralizing is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint response. While antibodies against the Spike protein have increased IgG binding capacity, they also have a significantly reduced neutralizing activity. The dramatic reductions in both IgG binding and ACE2 binding inhibition towards omicron as opposed to other VOC/VOI, confirm this variant remains capable of immune escape and requires careful sequence monitoring to identify any further sequence evolution. Importantly, booster doses elicit a significant increase in antibody response which correlates with a significant increase in both IgG binding and ACE2 binding inhibition against omicron. Our data adds weight a growing body of evidence that the continuous adaptation of vaccines to novel highly contagious variants needs to be considered in order to eliminate SARS-CoV-2. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint

NSM was a speaker at previous Luminex user meetings. The NMI is involved in applied research projects as a fee for services with the Luminex Corporation. All other authors declare no competing interests. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint

Binding response by pre-existing antibodies generated through either infection or is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint compared to all other variants of concern for both infected and vaccinated samples. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 1, 2022. ; https://doi.org/10.1101/2021.12.30.21267519 doi: medRxiv preprint

)-sarscov-2-variant-of-concern: WHO; 2021 [updated 26

Plasma neutralization properties of the SARS-CoV-2 Omicron variant

Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Broad neutralization of SARS-CoV-2 variants, including omicron, following breakthrough infection with delta in COVID-19 vaccinated individuals

Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies

SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. The Lancet Public Health

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

The biological and clinical significance of emerging SARS-CoV-2 variants

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa

Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants

Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate

We would like to thank other members of the Multiplex Immunoassays, Biological Development Center and Bioanalytics groups at the NMI for their support on this project. We would like to thank Ann Kathrin Horlacher and Mareike Walenta for assistance with sample processing and patient material storage. We Ulrike Schmidt,